There is some evidence that ALA can reduce markers of inflammation, such as: C-reactive protein Interleukin-6 Tumor necrosis factor-alpha, which promotes insulin resistance and is associated with type 2 diabetes High levels of C-reactive protein are considered a risk factor for heart disease
doi:10.1001/archotol.1993.01880180068013
Neuropsychiatric safety with liraglutide 30 mg for weight management: results from randomized controlled phase 2 and 3a trials
J Neuropathol Exp Neurol 68(7):797808 Beymer C, Kowdley KV, Larson A, Edmonson P, Dellinger EP, Flum DR (2003) Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery
(PubMed) Reinhart KM, Coleman CI, Teevan C, Vachhani P, White CM
Note: After the Food and Drug Administration (FDA) approves a drug, it tracks and reviews side effects of the medication